CorMedix (CRMD) EPS (Weighted Average and Diluted) (2021 - 2025)
CorMedix has reported EPS (Weighted Average and Diluted) over the past 7 years, most recently at $0.07 for Q4 2025.
- Quarterly results put EPS (Weighted Average and Diluted) at $0.07 for Q4 2025, down 70.83% from a year ago — trailing twelve months through Dec 2025 was $1.91 (up 716.13% YoY), and the annual figure for FY2025 was $2.04, up 780.0%.
- EPS (Weighted Average and Diluted) reached $0.07 in Q4 2025 per CRMD's latest filing, down from $1.26 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $1.26 in Q3 2025 and bottomed at -$0.26 in Q4 2023.
- Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.05 (2024), compared with a mean of $0.04.
- The largest annual shift saw EPS (Weighted Average and Diluted) crashed 230.95% in 2023 before it skyrocketed 2620.0% in 2025.
- Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.26 in 2021, then increased by 20.58% to -$0.2 in 2022, then fell by 27.56% to -$0.26 in 2023, then skyrocketed by 192.31% to $0.24 in 2024, then crashed by 70.83% to $0.07 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for CRMD at $0.07 in Q4 2025, $1.26 in Q3 2025, and $0.28 in Q2 2025.